d3 receptor

BP14979 is a dopamine D3 receptor agonist that can be used to study neurological disorders.

GSK 789472 hydrochloride is both a dopamine D3 receptor antagonist and a D2 partial agonist.

SK609 HCl (SK609 hydrochloride) is a dopamine D3 receptor (D3R) selective agonist that inhibits norepinephrine transporter proteins and can be used to study Parkinson's disease and cognitive disorders.

PD128907 HCl is a potent and selective dopamine D3 receptor agonist, with EC50 of 0.64 nM, exhibits 53-fold selectivity over dopamine D2 receptor.

(-)-GSK598809 hydrochloride is the isomer of GSK598809. GSK598809 is a selective antagonist of the dopamine D3 receptor (DRD3), which is a neural response that selectively enhances reward anticipation in drug and alcohol dependence during monetary policy and may repair reward deficits in substance dependence.

Dopamine D3 receptor antagonist-1 is a dopamine D3 receptor-selective or multi-targeting ligand with a Ki value of 1.58 nM, showing therapeutic potential for central nervous system disorders.

Dopamine D3 receptor agonist 13a selectively targets the dopamine D3 receptor over dopamine D1, D2, and D4 receptors, with affinities (Ki values) of 0.14, 4,600, 2.85, and 756 nM, respectively. It also interacts with serotonin (5-HT) receptor subtypes 5-HT1A, 5-HT2A, 5-HT2B, and 5-HT2C, with Ki values of 6, 54, 1.47, and 252 nM, respectively. While acting as a partial agonist at dopamine D2 receptors (EC50 = 2.26 nM in a G protein recruitment assay), it serves as an antagonist at dopamine D3 receptors (IC50 = 4.62 nM). Additionally, Dopamine D3 receptor agonist 13a, at a dose of 3 mg kg, has been shown to reduce cocaine self-administration in rats.

Dopamine D3 receptor antagonist-2 is a dopamine D3 receptor-selective compound (Ki=2.16 nM) that exhibits potential therapeutic effects in CNS disorders.

Dopamine D3 receptor ligand is a potent, selective, high-affinity compound with 89 times greater selectivity for D3 receptors (Ki: 8 nM) compared to D2 receptors (Ki: 715 nM).

D3 5-HT receptor modulator-1 (compound 5i) is a selective antagonist of the dopamine D3 and 5-HT2A receptors, and a partial agonist at the 5-HT1A receptor. It exhibits Ki values of 4.5 nM, 11.9 nM, and 15.3 nM for the dopamine D3, 5-HT2A, and 5-HT1A receptors respectively. The compound shows lower affinity for the dopamine D2 receptor, 5-HT2C receptor, and hERG channel. D3 5-HT receptor modulator-1 possesses atypical antipsychotic properties.

PNU-177864 hydrochloride is a potent, selective, and orally active dopamine D3 receptor antagonist that is structurally consistent with a cationic amphiphilic drug (CAD). It induces phospholipidosis in vivo and exhibits antischizophrenic activity.

A-437203 (Lu201640) is A kind of based on 1 h - pyrimidin - 2 - one sca ff old, selective, new powerful d3 receptor antagonist, on D2, d3, and D4 receptor, Ki value 71, respectively 1.6 and 6220 nM.

NGD 94-1 is a selective D4 receptor antagonist with an affinity of 3 nM for the D4 receptor and greater than 2 pM for the D1, D2, D3, and D5 receptors.NGD 94-1 can be used in the study of cognitive disorders and other psychiatric disorders.

PD 168568 dihydrochloride (PD 168568 (dihydrochloride)) is an orally active and selective antagonist of D4 dopamine receptor(Ki of 8.8 nM).

Aplindore Fumarate (DAB-452) is a small molecule dopamine D2 receptor partial agonist.Aplindore Fumarate exhibits high affinity for dopamine D2 and D3 receptors, and low affinity for dopamine D4, 5-hydroxytryptophan (5-HT2), and α1-adrenergic receptors.Aplindore Fumarate is used in the study of Parkinson's disease and schizophrenia. Fumarate can be used to study Parkinson's and schizophrenia.

Perphenazine dihydrochloride is an orally active dopamine receptor and histamine-1 receptor antagonist that acts on D2 (Ki: 0.56 nM), D3 (Ki: 0.43 nM), and 5-HT2A (Ki: 0.6 nM) receptors, and also binds Alpha-1A adrenergic receptors. It can induce apoptosis, inhibit cancer cell proliferation, and is used to study psychiatric disorders, cancer, and inflammation.

SKF83959, a benzazepine analog, is a selective and potent partial agonist of the dopamine D1 receptor with Ki values of 1.18, 7.56, 920, and 399 nM for rat D1, D5, D2, and D3 receptors, respectively.SKF83959 is a potent variant modulator of the sigma (σ)-1 receptor, which ameliorates cognitive dysfunction for the study depression and Alzheimer's disease.

SB-277011 (SB-277011A) is a specific antagonist of the dopamine D3 receptor with pKi values of 8.0, 6.0, 5.0, and <5.2 for D3 receptor, D2 receptor, 5-HT1D, and 5-HT1B respectively.

Adoprazine (SLV313) is a potential atypical antipsychotic bearing potent D2 receptor antagonist and 5-HT1A receptor agonist properties.

Fallypride is a potent and selective dopamine D2 D3 receptor antagonist.

Didesmethyl cariprazine, a metabolite of Cariprazine, is the major cyclic active part. Didesmethyl cariprazine has a long half-life of 1-3 weeks. Cariprazine is a potent D3 preference D3 D2 receptor partial agonist of dopamine for the treatment of schizophrenia, bipolar mania, and depression, with a high affinity for d3 and d2 receptors and a moderate affinity for 5-HT 1A receptors.

SB-277011 hydrochloride (SB-277011A hydrochloride) is a potent, selective, and orally active dopamine D3 receptor (D3R) antagonist that crosses the blood-brain barrier, with Ki values of 10.7 nM for rodent D3R and 11.2 nM for human D3R. It is 80-100 times more selective for D3 receptors than other dopamine receptors, acting on D3 receptors (pKi: 8.0), D2 receptors (pKi: 6.0), 5-HT1B receptors (pKi < 5.2), and 5-HT1D receptors (pKi: 5.9).

Sarizotan 2HCl is an hERG channel inhibitor and 5-hydroxytryptamine 5-HT1A receptor agonist with potential antidepressant effects for the study of Parkinsonian movement disorders.

Trazpiroben (TAK-906) is a selective dopamine D2 D3 receptor antagonist utilized in gastroparesis research.